Innovation Acta participates in THANATOS, “THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX”, a new Horizon Europe project funded under HORIZON-HLTH-2025-01-DISEASE-03.
The project will start on 1 September and aims to develop and clinically validate ArAv87, a broad-spectrum, human-like recombinant antibody designed to neutralize all orthopoxviruses infectious for humans.
THANATOS addresses a major unmet medical need, as no specific and scalable therapy is currently available for orthopoxvirus infections. By combining artificial intelligence with gold-standard laboratory techniques, the consortium will work to optimize ArAv87 in terms of affinity, clinical tolerance, manufacturability, and stability, with the goal of advancing a first-in-class therapeutic solution from research to clinical application.
The consortium is coordinated by CEA – Commissariat à l’énergie atomique et aux énergies alternatives and brings together partners from France, Germany, Belgium, Sweden, Cameroon, and Italy.
Having supported the preparation of the proposal, Innovation Acta will now take care of the project’s administrative management, as well as communication and dissemination activities, supporting the effective implementation and visibility of this ambitious international initiative.